尿吡啶吡PYD ELISA试剂盒说明书美国Metre_其它资料_资料

尿吡啶啉PYD ELISA试剂盒 美国Quidel INTENDED USE
MicroVue PYD is a urinary assay that provides a quantitative measure of the excretion of pyridinium crosslinks as an indicator of type I collagen resorption, especially bone collagen.

尿吡啶啉PYD ELISA试剂盒美国Quidel SUMMARY AND EXPLANATION
Approximately 90% of the organic matrix of bone is type I collagen, a triple helical protein.1 Type I collagen of bone is crosslinked by specifi c molecules which provide rigidity and strength. Crosslinks of mature type I collagen in bone are the pyridinium crosslinks, pyridinoline (PYD) and deoxypyridinoline (DPD).1,2 PYD and DPD are formed by the enzymatic action of lysyl oxidase on the amino acid lysine.3 They are released into the circulation during the bone resorption process.2-5 Pyridinium crosslinks are excreted unmetabolized in urine and are unaff ected by diet,6 making them suitable for assessing resorption. Bone is constantly undergoing a metabolic process calledremodeling.2,7 This includes a degradation process, bone resorption,mediated by the action of osteoclasts, and a building process, bone formation, mediated by the action of osteoblasts.2,7 Remodeling is required for the maintenance and overall health of bone and is tightly coupled; that is, resorption and formation are in balance.7 In abnormal states of bone metabolism this process becomes uncoupled and, when resorption exceeds formation, this results in a net loss of bone.7 The measurement of specifi c degradation products of bone matrix provide analytical data of the rate of bone metabolism.2,4,5 Osteoporosis is a metabolic bone disease characterized by abnormal bone remodeling. It is a systemic skeletal disease characterized by
low bone mass and Microarchitectural deterioration of bone tissue, with a consequent increase in susceptibility to fractures.8 The most common type of osteoporosis occurs in postmenopausal women as a result of the estrogen defi ciency produced by the cessation of ovarian function.7 Restoration of premenopausal estrogen levels by replacement therapy prevents bone loss and osteoporosis.7-9 Estrogens and a class of compounds known as bisphosphonates are antiresorptive therapies which can be used to prevent bone loss or treat osteoporosis.7-10 Osteoporosis can also result from attaining an inadequate peak bone mass during the growing years, an age-related imbalance of bone remodeling with a net excess of resorption, and a number of clinical conditions and therapies which induce bone loss or bone remodeling imbalances.7 These include endocrine diseases such as hypogonadism, hyperthyroidism,
hyperparathyroidism, and hypercortisolism; gastrointestinal diseases related to nutrition and mineral metabolism; connective tissue diseases; multiple myeloma; chronic immobilization, alcoholism, or tobacco use; and chronic therapy with heparin or corticosteroids.7 Other diseases characterized by abnormal bone remodeling include Paget’s disease and cancers metastatic to bone.3 For the MicroVue PYD assay, technology was employed to produce a monoclonal antibody that demonstrates specifi city for pyridinium crosslinks.11 The specifi city of the monoclonal antibody used in the MicroVue PYD assay allows for simple, convenient, reproducible and direct quantitation of PYD and DPD in urine.

关键词:骨胶原,低骨量,骨质疏松症,性腺功能低下,多发性骨髓瘤,胃肠道疾病,甲状腺功能亢进,佩吉特氏病

http://www.craymeibio.com/

尿吡啶吡PYD ELISA试剂盒说明书 美国Metre

尿吡啶吡PYD ELISA试剂盒说明书美国Metre